Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 49 entries
Sorted by: Best Match Show Resources per page
Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations.

Oncotarget

Masuzawa K, Yasuda H, Hamamoto J, Nukaga S, Hirano T, Kawada I, Naoki K, Soejima K, Betsuyaku T.
PMID: 29285266
Oncotarget. 2017 Nov 06;8(62):105479-105491. doi: 10.18632/oncotarget.22297. eCollection 2017 Dec 01.

Third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) were developed to overcome

Cite
Masuzawa K, Yasuda H, Hamamoto J, et al. Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations. Oncotarget. 2017;8(62):105479-105491doi: 10.18632/oncotarget.22297.
Masuzawa, K., Yasuda, H., Hamamoto, J., Nukaga, S., Hirano, T., Kawada, I., Naoki, K., Soejima, K., & Betsuyaku, T. (2017). Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations. Oncotarget, 8(62), 105479-105491. https://doi.org/10.18632/oncotarget.22297
Masuzawa, Keita, et al. "Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations." Oncotarget vol. 8,62 (2017): 105479-105491. doi: https://doi.org/10.18632/oncotarget.22297
Masuzawa K, Yasuda H, Hamamoto J, Nukaga S, Hirano T, Kawada I, Naoki K, Soejima K, Betsuyaku T. Characterization of the efficacies of osimertinib and nazartinib against cells expressing clinically relevant epidermal growth factor receptor mutations. Oncotarget. 2017 Nov 06;8(62):105479-105491. doi: 10.18632/oncotarget.22297. eCollection 2017 Dec 01. PMID: 29285266; PMCID: PMC5739653.
Copy Download .nbib Format: NLM
Thermofield transfer-matrix method and its applications to quantum spin systems.

Physical review. B, Condensed matter

Betsuyaku H, Suzuki M.
PMID: 9939840
Phys Rev B Condens Matter. 1986 Aug 01;34(3):1829-1834. doi: 10.1103/physrevb.34.1829.

No abstract available.

Cite
Betsuyaku H, Suzuki M. Thermofield transfer-matrix method and its applications to quantum spin systems. Phys Rev B Condens Matter. 1986;34(3):1829-1834doi: 10.1103/physrevb.34.1829.
Betsuyaku, H., & Suzuki, M. (1986). Thermofield transfer-matrix method and its applications to quantum spin systems. Physical review. B, Condensed matter, 34(3), 1829-1834. https://doi.org/10.1103/physrevb.34.1829
Betsuyaku, and Suzuki. "Thermofield transfer-matrix method and its applications to quantum spin systems." Physical review. B, Condensed matter vol. 34,3 (1986): 1829-1834. doi: https://doi.org/10.1103/physrevb.34.1829
Betsuyaku H, Suzuki M. Thermofield transfer-matrix method and its applications to quantum spin systems. Phys Rev B Condens Matter. 1986 Aug 01;34(3):1829-1834. doi: 10.1103/physrevb.34.1829. PMID: 9939840.
Copy Download .nbib Format: NLM
Mechanisms to Suppress ILC2-induced Airway Inflammation.

Annals of the American Thoracic Society

Kabata H, Moro K, Koyasu S, Fukunaga K, Asano K, Betsuyaku T.
PMID: 27027961
Ann Am Thorac Soc. 2016 Mar;13:S95. doi: 10.1513/AnnalsATS.201508-557MG.

Epithelial cell-derived cytokines such as IL-33 and IL-25 activate group 2 innate lymphoid cells (ILC2s), which are known to be important sources of type 2 cytokines such as IL-5 and IL-13 in a variety of asthma mouse models. Recently,...

Cite
Kabata H, Moro K, Koyasu S, et al. Mechanisms to Suppress ILC2-induced Airway Inflammation. Ann Am Thorac Soc. 2016;13:S95doi: 10.1513/AnnalsATS.201508-557MG.
Kabata, H., Moro, K., Koyasu, S., Fukunaga, K., Asano, K., & Betsuyaku, T. (2016). Mechanisms to Suppress ILC2-induced Airway Inflammation. Annals of the American Thoracic Society, 13S95. https://doi.org/10.1513/AnnalsATS.201508-557MG
Kabata, Hiroki, et al. "Mechanisms to Suppress ILC2-induced Airway Inflammation." Annals of the American Thoracic Society vol. 13 (2016): S95. doi: https://doi.org/10.1513/AnnalsATS.201508-557MG
Kabata H, Moro K, Koyasu S, Fukunaga K, Asano K, Betsuyaku T. Mechanisms to Suppress ILC2-induced Airway Inflammation. Ann Am Thorac Soc. 2016 Mar;13:S95. doi: 10.1513/AnnalsATS.201508-557MG. PMID: 27027961.
Copy Download .nbib Format: NLM
Levels of Soluble Receptor for Advanced Glycation End Products in Bronchoalveolar Lavage Fluid in Patients with Various Inflammatory Lung Diseases.

Clinical medicine insights. Circulatory, respiratory and pulmonary medicine

Kamo T, Tasaka S, Tokuda Y, Suzuki S, Asakura T, Yagi K, Namkoong H, Ishii M, Hasegawa N, Betsuyaku T.
PMID: 27147899
Clin Med Insights Circ Respir Pulm Med. 2016 Apr 28;9:147-54. doi: 10.4137/CCRPM.S23326. eCollection 2015.

Receptor for advanced glycation end products (RAGE) is a multiligand receptor of S100/calgranulins, high-mobility group box 1, and others, and it is associated with the pathogenesis of various inflammatory and circulatory diseases. The soluble form of RAGE (sRAGE) is...

Cite
Kamo T, Tasaka S, Tokuda Y, et al. Levels of Soluble Receptor for Advanced Glycation End Products in Bronchoalveolar Lavage Fluid in Patients with Various Inflammatory Lung Diseases. Clin Med Insights Circ Respir Pulm Med. 2016;9:147-54doi: 10.4137/CCRPM.S23326.
Kamo, T., Tasaka, S., Tokuda, Y., Suzuki, S., Asakura, T., Yagi, K., Namkoong, H., Ishii, M., Hasegawa, N., & Betsuyaku, T. (2015). Levels of Soluble Receptor for Advanced Glycation End Products in Bronchoalveolar Lavage Fluid in Patients with Various Inflammatory Lung Diseases. Clinical medicine insights. Circulatory, respiratory and pulmonary medicine, 9147-54. https://doi.org/10.4137/CCRPM.S23326
Kamo, Tetsuro, et al. "Levels of Soluble Receptor for Advanced Glycation End Products in Bronchoalveolar Lavage Fluid in Patients with Various Inflammatory Lung Diseases." Clinical medicine insights. Circulatory, respiratory and pulmonary medicine vol. 9 (2015): 147-54. doi: https://doi.org/10.4137/CCRPM.S23326
Kamo T, Tasaka S, Tokuda Y, Suzuki S, Asakura T, Yagi K, Namkoong H, Ishii M, Hasegawa N, Betsuyaku T. Levels of Soluble Receptor for Advanced Glycation End Products in Bronchoalveolar Lavage Fluid in Patients with Various Inflammatory Lung Diseases. Clin Med Insights Circ Respir Pulm Med. 2016 Apr 28;9:147-54. doi: 10.4137/CCRPM.S23326. eCollection 2015. PMID: 27147899; PMCID: PMC4852761.
Copy Download .nbib Format: NLM
Alectinib as a treatment option following recovery from crizotinib-induced interstitial lung disease in patients with anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer.

Molecular and clinical oncology

Nukaga S, Naoki K, Kamo T, Masuzawa K, Yasuda H, Soejima K, Betsuyaku T.
PMID: 27284449
Mol Clin Oncol. 2016 Jun;4(6):1085-1087. doi: 10.3892/mco.2016.838. Epub 2016 Mar 30.

Crizotinib is a tyrosine kinase inhibitor that displays antitumor activity against anaplastic lymphoma kinase (

Cite
Nukaga S, Naoki K, Kamo T, et al. Alectinib as a treatment option following recovery from crizotinib-induced interstitial lung disease in patients with anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. Mol Clin Oncol. 2016;4(6):1085-1087doi: 10.3892/mco.2016.838.
Nukaga, S., Naoki, K., Kamo, T., Masuzawa, K., Yasuda, H., Soejima, K., & Betsuyaku, T. (2016). Alectinib as a treatment option following recovery from crizotinib-induced interstitial lung disease in patients with anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. Molecular and clinical oncology, 4(6), 1085-1087. https://doi.org/10.3892/mco.2016.838
Nukaga, Shigenari, et al. "Alectinib as a treatment option following recovery from crizotinib-induced interstitial lung disease in patients with anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer." Molecular and clinical oncology vol. 4,6 (2016): 1085-1087. doi: https://doi.org/10.3892/mco.2016.838
Nukaga S, Naoki K, Kamo T, Masuzawa K, Yasuda H, Soejima K, Betsuyaku T. Alectinib as a treatment option following recovery from crizotinib-induced interstitial lung disease in patients with anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. Mol Clin Oncol. 2016 Jun;4(6):1085-1087. doi: 10.3892/mco.2016.838. Epub 2016 Mar 30. PMID: 27284449; PMCID: PMC4888013.
Copy Download .nbib Format: NLM
Root-specific CLE3 expression is required for WRKY33 activation in Arabidopsis shoots.

Plant molecular biology

Ma D, Endo S, Betsuyaku E, Fujiwara T, Betsuyaku S, Fukuda H.
PMID: 35038066
Plant Mol Biol. 2022 Jan 17; doi: 10.1007/s11103-021-01234-9. Epub 2022 Jan 17.

KEY MESSAGE: This study focused on the role of CLE1-7 peptides as defense mediators, and showed that root-expressed CLE3 functions as a systemic signal to regulate defense-related gene expression in shoots. In the natural environment, plants employ diverse signaling...

Cite
Ma D, Endo S, Betsuyaku E, et al. Root-specific CLE3 expression is required for WRKY33 activation in Arabidopsis shoots. Plant Mol Biol. 2022;doi: 10.1007/s11103-021-01234-9.
Ma, D., Endo, S., Betsuyaku, E., Fujiwara, T., Betsuyaku, S., & Fukuda, H. (2022). Root-specific CLE3 expression is required for WRKY33 activation in Arabidopsis shoots. Plant molecular biology, . https://doi.org/10.1007/s11103-021-01234-9
Ma, Dichao, et al. "Root-specific CLE3 expression is required for WRKY33 activation in Arabidopsis shoots." Plant molecular biology vol. (2022). doi: https://doi.org/10.1007/s11103-021-01234-9
Ma D, Endo S, Betsuyaku E, Fujiwara T, Betsuyaku S, Fukuda H. Root-specific CLE3 expression is required for WRKY33 activation in Arabidopsis shoots. Plant Mol Biol. 2022 Jan 17; doi: 10.1007/s11103-021-01234-9. Epub 2022 Jan 17. PMID: 35038066.
Copy Download .nbib Format: NLM
Upregulation of FGF9 in Lung Adenocarcinoma Transdifferentiation to Small Cell Lung Cancer.

Cancer research

Ishioka K, Yasuda H, Hamamoto J, Terai H, Emoto K, Kim TJ, Hirose S, Kamatani T, Mimaki S, Arai D, Ohgino K, Tani T, Masuzawa K, Manabe T, Shinozaki T, Mitsuishi A, Ebisudani T, Fukushima T, Ozaki M, Ikemura S, Kawada I, Naoki K, Nakamura M, Ohtsuka T, Asamura H, Tsuchihara K, Hayashi Y, Hegab AE, Kobayashi SS, Kohno T, Watanabe H, Ornitz DM, Betsuyaku T, Soejima K, Fukunaga K.
PMID: 34083250
Cancer Res. 2021 Jul 15;81(14):3916-3929. doi: 10.1158/0008-5472.CAN-20-4048. Epub 2021 Jun 03.

Transdifferentiation of lung adenocarcinoma to small cell lung cancer (SCLC) has been reported in a subset of lung cancer cases that bear EGFR mutations. Several studies have reported the prerequisite role of

Cite
Ishioka K, Yasuda H, Hamamoto J, et al. Upregulation of FGF9 in Lung Adenocarcinoma Transdifferentiation to Small Cell Lung Cancer. Cancer Res. 2021;81(14):3916-3929doi: 10.1158/0008-5472.CAN-20-4048.
Ishioka, K., Yasuda, H., Hamamoto, J., Terai, H., Emoto, K., Kim, T. J., Hirose, S., Kamatani, T., Mimaki, S., Arai, D., Ohgino, K., Tani, T., Masuzawa, K., Manabe, T., Shinozaki, T., Mitsuishi, A., Ebisudani, T., Fukushima, T., Ozaki, M., Ikemura, S., Kawada, I., Naoki, K., Nakamura, M., Ohtsuka, T., Asamura, H., Tsuchihara, K., Hayashi, Y., Hegab, A. E., Kobayashi, S. S., Kohno, T., Watanabe, H., Ornitz, D. M., Betsuyaku, T., Soejima, K., & Fukunaga, K. (2021). Upregulation of FGF9 in Lung Adenocarcinoma Transdifferentiation to Small Cell Lung Cancer. Cancer research, 81(14), 3916-3929. https://doi.org/10.1158/0008-5472.CAN-20-4048
Ishioka, Kota, et al. "Upregulation of FGF9 in Lung Adenocarcinoma Transdifferentiation to Small Cell Lung Cancer." Cancer research vol. 81,14 (2021): 3916-3929. doi: https://doi.org/10.1158/0008-5472.CAN-20-4048
Ishioka K, Yasuda H, Hamamoto J, Terai H, Emoto K, Kim TJ, Hirose S, Kamatani T, Mimaki S, Arai D, Ohgino K, Tani T, Masuzawa K, Manabe T, Shinozaki T, Mitsuishi A, Ebisudani T, Fukushima T, Ozaki M, Ikemura S, Kawada I, Naoki K, Nakamura M, Ohtsuka T, Asamura H, Tsuchihara K, Hayashi Y, Hegab AE, Kobayashi SS, Kohno T, Watanabe H, Ornitz DM, Betsuyaku T, Soejima K, Fukunaga K. Upregulation of FGF9 in Lung Adenocarcinoma Transdifferentiation to Small Cell Lung Cancer. Cancer Res. 2021 Jul 15;81(14):3916-3929. doi: 10.1158/0008-5472.CAN-20-4048. Epub 2021 Jun 03. PMID: 34083250.
Copy Download .nbib Format: NLM
Risk factors for poor adherence to inhaled corticosteroid therapy in patients with moderate to severe asthma.

Asian Pacific journal of allergy and immunology

Masaki K, Miyata J, Kamatani T, Tanosaki T, Mochimaru T, Kabata H, Suzuki Y, Asano K, Betsuyaku T, Fukunaga K.
PMID: 32563226
Asian Pac J Allergy Immunol. 2020 Jun 21; doi: 10.12932/AP-311219-0731. Epub 2020 Jun 21.

BACKGROUND: Poor adherence to inhaled corticosteroid (ICS) therapy is a common reason for worsened asthma control.OBJECTIVE: We investigated the characteristics of patients with moderate to severe asthma who showed poor adherence to therapy, to identify the barriers for optimal...

Cite
Masaki K, Miyata J, Kamatani T, et al. Risk factors for poor adherence to inhaled corticosteroid therapy in patients with moderate to severe asthma. Asian Pac J Allergy Immunol. 2020;doi: 10.12932/AP-311219-0731.
Masaki, K., Miyata, J., Kamatani, T., Tanosaki, T., Mochimaru, T., Kabata, H., Suzuki, Y., Asano, K., Betsuyaku, T., & Fukunaga, K. (2020). Risk factors for poor adherence to inhaled corticosteroid therapy in patients with moderate to severe asthma. Asian Pacific journal of allergy and immunology, . https://doi.org/10.12932/AP-311219-0731
Masaki, Katsunori, et al. "Risk factors for poor adherence to inhaled corticosteroid therapy in patients with moderate to severe asthma." Asian Pacific journal of allergy and immunology vol. (2020). doi: https://doi.org/10.12932/AP-311219-0731
Masaki K, Miyata J, Kamatani T, Tanosaki T, Mochimaru T, Kabata H, Suzuki Y, Asano K, Betsuyaku T, Fukunaga K. Risk factors for poor adherence to inhaled corticosteroid therapy in patients with moderate to severe asthma. Asian Pac J Allergy Immunol. 2020 Jun 21; doi: 10.12932/AP-311219-0731. Epub 2020 Jun 21. PMID: 32563226.
Copy Download .nbib Format: NLM
Factors associated with improvements in subjective symptoms of obstructive sleep apnea syndrome after continuous positive airway pressure therapy.

Sleep & breathing = Schlaf & Atmung

Otsuka K, Fukunaga K, WakakoYamasawa, Haraguchi M, Tani T, Shirahama R, Betsuyaku T.
PMID: 31280400
Sleep Breath. 2020 Jun;24(2):491-498. doi: 10.1007/s11325-019-01877-5. Epub 2019 Jul 06.

PURPOSE: Continuous positive airway pressure (CPAP) therapy improves subjective symptoms in obstructive sleep apnea syndrome (OSAS) patients; however, factors predicting symptom improvement post-CPAP therapy and the CPAP duration necessary for improving subjective symptoms are unclear. This study aimed to...

Cite
Otsuka K, Fukunaga K, WakakoYamasawa, et al. Factors associated with improvements in subjective symptoms of obstructive sleep apnea syndrome after continuous positive airway pressure therapy. Sleep Breath. 2019;24(2):491-498doi: 10.1007/s11325-019-01877-5.
Otsuka, K., Fukunaga, K., WakakoYamasawa, Haraguchi, M., Tani, T., Shirahama, R., & Betsuyaku, T. (2020). Factors associated with improvements in subjective symptoms of obstructive sleep apnea syndrome after continuous positive airway pressure therapy. Sleep & breathing = Schlaf & Atmung, 24(2), 491-498. https://doi.org/10.1007/s11325-019-01877-5
Otsuka, Kengo, et al. "Factors associated with improvements in subjective symptoms of obstructive sleep apnea syndrome after continuous positive airway pressure therapy." Sleep & breathing = Schlaf & Atmung vol. 24,2 (2020): 491-498. doi: https://doi.org/10.1007/s11325-019-01877-5
Otsuka K, Fukunaga K, WakakoYamasawa, Haraguchi M, Tani T, Shirahama R, Betsuyaku T. Factors associated with improvements in subjective symptoms of obstructive sleep apnea syndrome after continuous positive airway pressure therapy. Sleep Breath. 2020 Jun;24(2):491-498. doi: 10.1007/s11325-019-01877-5. Epub 2019 Jul 06. PMID: 31280400.
Copy Download .nbib Format: NLM
The Impact of Smoking on Pulmonary Metastasis in Colorectal Cancer.

OncoTargets and therapy

Makino A, Tsuruta M, Okabayashi K, Ishida T, Shigeta K, Seishima R, Ikebata A, Koishikawa K, Hasegawa H, Shimoda M, Fukunaga K, Betsuyaku T, Kitagawa Y.
PMID: 33061444
Onco Targets Ther. 2020 Sep 30;13:9623-9629. doi: 10.2147/OTT.S263250. eCollection 2020.

INTRODUCTION: Recently, clinical studies have revealed that smoking can contribute to the poor prognosis of colorectal cancer (CRC) and, additionally, can be a risk factor for pulmonary metastasis of CRC. However, there has been no basic research regarding the...

Cite
Makino A, Tsuruta M, Okabayashi K, et al. The Impact of Smoking on Pulmonary Metastasis in Colorectal Cancer. Onco Targets Ther. 2020;13:9623-9629doi: 10.2147/OTT.S263250.
Makino, A., Tsuruta, M., Okabayashi, K., Ishida, T., Shigeta, K., Seishima, R., Ikebata, A., Koishikawa, K., Hasegawa, H., Shimoda, M., Fukunaga, K., Betsuyaku, T., & Kitagawa, Y. (2020). The Impact of Smoking on Pulmonary Metastasis in Colorectal Cancer. OncoTargets and therapy, 139623-9629. https://doi.org/10.2147/OTT.S263250
Makino, Akitsugu, et al. "The Impact of Smoking on Pulmonary Metastasis in Colorectal Cancer." OncoTargets and therapy vol. 13 (2020): 9623-9629. doi: https://doi.org/10.2147/OTT.S263250
Makino A, Tsuruta M, Okabayashi K, Ishida T, Shigeta K, Seishima R, Ikebata A, Koishikawa K, Hasegawa H, Shimoda M, Fukunaga K, Betsuyaku T, Kitagawa Y. The Impact of Smoking on Pulmonary Metastasis in Colorectal Cancer. Onco Targets Ther. 2020 Sep 30;13:9623-9629. doi: 10.2147/OTT.S263250. eCollection 2020. PMID: 33061444; PMCID: PMC7533240.
Copy Download .nbib Format: NLM
Upregulation of FGF9 in Lung Adenocarcinoma Transdifferentiation to Small Cell Lung Cancer.

Cancer research

Ishioka K, Yasuda H, Hamamoto J, Terai H, Emoto K, Kim TJ, Hirose S, Kamatani T, Mimaki S, Arai D, Ohgino K, Tani T, Masuzawa K, Manabe T, Shinozaki T, Mitsuishi A, Ebisudani T, Fukushima T, Ozaki M, Ikemura S, Kawada I, Naoki K, Nakamura M, Ohtsuka T, Asamura H, Tsuchihara K, Hayashi Y, Hegab AE, Kobayashi SS, Kohno T, Watanabe H, Ornitz DM, Betsuyaku T, Soejima K, Fukunaga K.
PMID: 34083250
Cancer Res. 2021 Jul 15;81(14):3916-3929. doi: 10.1158/0008-5472.CAN-20-4048. Epub 2021 Jun 03.

Transdifferentiation of lung adenocarcinoma to small cell lung cancer (SCLC) has been reported in a subset of lung cancer cases that bear EGFR mutations. Several studies have reported the prerequisite role of

Cite
Ishioka K, Yasuda H, Hamamoto J, et al. Upregulation of FGF9 in Lung Adenocarcinoma Transdifferentiation to Small Cell Lung Cancer. Cancer Res. 2021;81(14):3916-3929doi: 10.1158/0008-5472.CAN-20-4048.
Ishioka, K., Yasuda, H., Hamamoto, J., Terai, H., Emoto, K., Kim, T. J., Hirose, S., Kamatani, T., Mimaki, S., Arai, D., Ohgino, K., Tani, T., Masuzawa, K., Manabe, T., Shinozaki, T., Mitsuishi, A., Ebisudani, T., Fukushima, T., Ozaki, M., Ikemura, S., Kawada, I., Naoki, K., Nakamura, M., Ohtsuka, T., Asamura, H., Tsuchihara, K., Hayashi, Y., Hegab, A. E., Kobayashi, S. S., Kohno, T., Watanabe, H., Ornitz, D. M., Betsuyaku, T., Soejima, K., & Fukunaga, K. (2021). Upregulation of FGF9 in Lung Adenocarcinoma Transdifferentiation to Small Cell Lung Cancer. Cancer research, 81(14), 3916-3929. https://doi.org/10.1158/0008-5472.CAN-20-4048
Ishioka, Kota, et al. "Upregulation of FGF9 in Lung Adenocarcinoma Transdifferentiation to Small Cell Lung Cancer." Cancer research vol. 81,14 (2021): 3916-3929. doi: https://doi.org/10.1158/0008-5472.CAN-20-4048
Ishioka K, Yasuda H, Hamamoto J, Terai H, Emoto K, Kim TJ, Hirose S, Kamatani T, Mimaki S, Arai D, Ohgino K, Tani T, Masuzawa K, Manabe T, Shinozaki T, Mitsuishi A, Ebisudani T, Fukushima T, Ozaki M, Ikemura S, Kawada I, Naoki K, Nakamura M, Ohtsuka T, Asamura H, Tsuchihara K, Hayashi Y, Hegab AE, Kobayashi SS, Kohno T, Watanabe H, Ornitz DM, Betsuyaku T, Soejima K, Fukunaga K. Upregulation of FGF9 in Lung Adenocarcinoma Transdifferentiation to Small Cell Lung Cancer. Cancer Res. 2021 Jul 15;81(14):3916-3929. doi: 10.1158/0008-5472.CAN-20-4048. Epub 2021 Jun 03. PMID: 34083250.
Copy Download .nbib Format: NLM
Reliability of measurement using Image J for reach distance and movement angles in the functional reach test.

Journal of physical therapy science

Suzuki T, Hashisdate H, Fujisawa Y, Yatsunami M, Ota T, Shimizu N, Betsuyaku T.
PMID: 33642684
J Phys Ther Sci. 2021 Feb;33(2):112-117. doi: 10.1589/jpts.33.112. Epub 2021 Feb 13.

[Purpose] The purpose of this study was to examine the test-retest reliability and minimal detectable change (MDC) of reach distance and movement angle analyses using Image J. [Participants and Methods] Thirty-eight healthy young males performed the functional reach test...

Cite
Suzuki T, Hashisdate H, Fujisawa Y, et al. Reliability of measurement using Image J for reach distance and movement angles in the functional reach test. J Phys Ther Sci. 2021;33(2):112-117doi: 10.1589/jpts.33.112.
Suzuki, T., Hashisdate, H., Fujisawa, Y., Yatsunami, M., Ota, T., Shimizu, N., & Betsuyaku, T. (2021). Reliability of measurement using Image J for reach distance and movement angles in the functional reach test. Journal of physical therapy science, 33(2), 112-117. https://doi.org/10.1589/jpts.33.112
Suzuki, Takayuki, et al. "Reliability of measurement using Image J for reach distance and movement angles in the functional reach test." Journal of physical therapy science vol. 33,2 (2021): 112-117. doi: https://doi.org/10.1589/jpts.33.112
Suzuki T, Hashisdate H, Fujisawa Y, Yatsunami M, Ota T, Shimizu N, Betsuyaku T. Reliability of measurement using Image J for reach distance and movement angles in the functional reach test. J Phys Ther Sci. 2021 Feb;33(2):112-117. doi: 10.1589/jpts.33.112. Epub 2021 Feb 13. PMID: 33642684; PMCID: PMC7897527.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 49 entries